Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery.

ABSTRACT: While anticancer drug discovery has seen dramatic innovations and successes, sequential single therapies are time-limited by resistance, and combinatorial strategies have been lagging. The number of possible drug combinations is vast. To select drug combinations the oncologist requires knowledge of the optimal combination of proteins to co-target. Currently, combinations that the oncologist considers are primarily from empirical observations and clinical praxis. Our aim is to develop a signaling-based method to discover optimal proteins for the oncologist to co-target with drug combinations, and test it on available, patient-derived data. To temper the expected resistance to single drug regimen, we offer a concept-based stratified pipeline aimed at selecting co-targets for drug combination

SUBMITTER: Yavuz BR 

PROVIDER: S-EPMC12646283 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature